XML 37 R20.htm IDEA: XBRL DOCUMENT v3.19.1
Restructuring
12 Months Ended
Dec. 31, 2018
Restructuring and Related Activities [Abstract]  
Restructuring
Restructuring

In May 2018, the Company commenced a reorganization plan to reduce its operating costs and better align its workforce with the needs of its business following the Company’s April 23, 2018 announcement of its decision to discontinue further development of NEOD001.

The Company incurred aggregate restructuring and impairment charges of approximately $16.1 million for the year ended December 31, 2018. Restructuring charges incurred under this plan primarily consisted of employee termination benefits and and contract termination costs primarily associated with exit fees relating to third-party manufacturers that we contracted with for NEOD001 clinical and commercial supplies. Employee termination benefits include severance costs, employee-related benefits, supplemental one-time termination payments and non-cash share-based compensation expense related to the acceleration of stock options. Charges and other costs related to the workforce reduction and structure realignment are presented as restructuring costs in the Consolidated Statements of Operations. Substantially all of the cash payments are expected to be paid out by the end of the first quarter of 2019. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring.

The following table summarizes the restructuring liability and utilization by cost type associated with the restructuring activities during the year ended December 31, 2018 (in thousands):

 
 
Restructuring Liability
 
 
Termination Benefits
 
Contract Termination Costs
 
Assets Impairment (1)
 
Other(2)
 
Total
Balance at January 31, 2018
 
$

 
$

 
$

 
$

 
$

Restructuring charges
 
8,187

 
5,922

 

 
613

 
14,722

Non cash charges
 
948

 
(23
)
 
498

 

 
1,423

Reduction in non cash charges
 
(948
)
 
23

 
(498
)
 

 
(1,423
)
Reductions for cash payments
 
(7,716
)
 
(5,655
)
 

 
(613
)
 
(13,984
)
Foreign Exchange
 
(10
)
 
(267
)
 

 

 
(277
)
Balance at December 31, 2018
 
$
461

 
$

 
$

 
$

 
$
461

(1) Includes $0.5 million of long-lived assets surrendered to the landlord as part of the full and final settlement of our office lease in Dún Laoghaire, Ireland as discussed in Note 7, "Commitments and Contingencies".
(2) Includes $0.6 million of costs incurred related to the sub-sublease of the Current SSF Facility as discussed in Note 7, “Commitments and Contingencies”.

The total amount expected to be incurred in connection with the restructuring plan is $16.1 million. The cumulative amount incurred to date is $16.1 million as of December 31, 2018. As of December 31, 2018, the restructuring liability is included in current liabilities on the Consolidated Balance Sheets.